Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication.
Dimethylfumarate protects against TNF-α-induced secretion of inflammatory cytokines in human endothelial cells.
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories.
The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro.
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
Clinical utility of the list sign as a predictor of non-demyelinating disorders in a multiple sclerosis (MS) practice.
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Flupirtine
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells.
Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.
Spectrum of nontraumatic myelopathies in Ethiopian patients: hospital-based retrospective study.
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
A gender gap in autoimmunity.
Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.
Monoclonal antibodies in MS: mechanisms of action.
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
A Pilot Trial of Interferon beta-1a in Alzheimer's Disease
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound.
Genzyme reports positive top-line results of TOWER, a pivotal phase III trial for AUBAGIO(TM*) (teriflunomide) in relapsing multiple sclerosis

Pages